What were the Phase 3 trial results?

The Triumph-2 and Triumph-3 trials met the primary endpoint of weight loss, but detailed results have not been released yet.

When will retatrutide be available?

No date set. Lilly will file for FDA approval in the coming months.

How does retatrutide compare to other obesity drugs?

It will compete with Wegovy and Mounjaro, and may be a strong option due to its triple mechanism.

Eli Lilly Closer to New Weight-Loss Drug: Retatrutide Passes Two Phase 3 Trials

Eli Lilly (LLY) announced that its experimental triple hormone receptor agonist retatrutide met the primary endpoint in two Phase 3 trials (Triumph-2 and Triumph-3) for obesity. This brings the company closer to filing for FDA approval.

July 23, 2026

2 min read

Source: Stocktwits

Eli Lilly (LLY) today announced that its experimental weight-loss drug, retatrutide, met the primary endpoint in two Phase 3 trials, paving the way for an FDA submission.

The Drug

Retatrutide is a once-weekly triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. It aims to improve weight loss and glycemic control.

Clinical Trials

The Triumph-2 and Triumph-3 trials demonstrated significant weight loss compared to placebo. Detailed results have not been disclosed but will be presented at an upcoming medical conference.

Pricing and Availability

Pricing and launch timeline have not been announced. Lilly plans to file for FDA approval in the coming months.

Competition

Retatrutide will compete with other weight-loss drugs like Wegovy (Novo Nordisk) and Lilly's own Mounjaro. If approved, it could become a strong contender in the growing obesity market.

Potential Impact on Company

Retatrutide represents a significant opportunity for Lilly to expand its obesity portfolio, especially given the success of Mounjaro and Zepbound. Approval could substantially boost Lilly's revenue.

Frequently Asked Questions

Retatrutide is an experimental weight-loss drug from Eli Lilly, administered once weekly, targeting GIP, GLP-1, and glucagon receptors.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.